Debio 0633
Oncology
The Debio 0633 program is a potential 1st-in-class ADC integrating our Multilink™ linker technology. This novel target can be leveraged to address multiple tumor types with high unmet medical needs.
In short
This ADC program uses highly innovative antibodies in-licensed from Genome & Company, a publicly traded biotech based in South Korea
Discovery stage development of a potential 1st-in-class therapeutic agents to outsmart hard-to-treat cancers
Our collaboration with Genome & Company
Genome & Company is a South Korean-based biotechnology company specializing in discovery and development of novel cancer targeting antibodies as stand-alone therapy and antibody-drug conjugate (ADC) applications. An agreement was reached in June 2024 for the development of ADCs with first-in-class potential. Genome’s innovative antibodies align well with Debiopharm’s development focus due to the target novelty and its expression in tumor types with high unmet needs.
Ongoing Development of Debio 0633
Plans for the advancement of the Debio 0633 program will continue the drug discovery phase, optimizing medicinal chemistry and metabolic stability. When the compound reaches the Preclinical Candidate stage, we will apply our drug development expertise in Translational Medicine including translational pharmacology, personalized medicine, biomarker investigations & companion diagnostics, toxicology, bioanalysis, nonclinical DMPK, clinical pharmacology and pharmacometrics.
Debiopharm’s ADC portfolio
We’re developing fit-for-purpose antibody drug conjugates through a tailored “Trifecta” approach: strategic target selection, innovative Multilink™ linker technology and smart payload choices. Our broad and balanced 1st-in-class or best-in-class ADC portfolio include Debio 0633 (undisclosed target), Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) Myelodysplastic syndromes (MDS) and Debio 0532, an HER3-targeted ADC for solid tumors, as well other undisclosed targets including proprietary bispecific ADC. Key partnerships also comprise options to in-licence bispecific antibodies targeting HER2-HER3 and HER3-EGFR along with additional undisclosed targets.
Designed with Multilink™ Technology
Our ADCs are designed with Multilink™ proprietary cleavable linker technology, allowing both high DAR and high stability and are being developed with smart payload choices. This technology is a new peptidic cleavable linker platform suited for multidrug attachment and compatible with any ADC conjugation technology. We are continuing to invest in our ADC platform, exploring potential game changing technologies such as novel and multiple payloads, leveraging our solid development experience to accelerate ADC products to patients.
